‹ÆÑ

2016E2015 E2014E2013E2012E2011E2010

ƒJƒeƒSƒŠ[•Ê

2017

(˜_•¶)

Hosen N, Matsunaga Y, Hasegawa K, Matsuno H, Nakamura Y, Makita M, Watanabe K, Yoshida M, Satoh K, Morimoto S, Fujiki F, Nakajima H, Nakata J, Nishida S, Tsuboi A, Oka Y, Manabe M, Ichihara H, Aoyama Y, Mugitani A, Nakao T, Hino M, Uchibori R, Ozawa K, Baba Y, Terakura S, Wada N, Morii E, Nishimura J, Takeda K, Oji Y, Sugiyama H, Takagi J, Kumanogoh A.
@
The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy

Nakamae H, Fukuda T, Nakaseko C, Kanda Y, Ohmine K, Ono T, Matsumura I, Matsuda A, Aoki M, Ito K, Shibayama H
@
Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.

Iriyama N, Kazuteru O, Hashino S, Kimura S, Nakaseko C, Takano H, Hino M, Uchiyama M, Morita S, Sakamoto J, Sakamaki H, Inokuchi K.
@
The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group

Goto T, Tanaka T, Sawa M, Ueda Y, Ago H, Chiba S, Kanamori H, Nishikawa A, Nougawa M, Ohashi K, Okumura H, Tanimoto M, Fukuda T, Kawashima N, Kato T, Okada K, Nagafuji K, Okamoto SI, Atsuta Y, Hino M, Tanaka J, Miyamura K.
@
Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan.

Kirito K, Suzuki K, Miyamura K, Takeuchi M, Handa H, Okamoto S, Gadbaw B, Yamauchi K, Amagasaki T, Ito K, Hino M.
@
Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly

Ido K, Aoyama Y, Nagasaki J, Koh S, Ichihara H, Harada H, Kawano K, Tani Y, Matsuyama N, Hirayama F, Kohsaki M, Takaku S, Mugitani A.
@
Pulmonary Involvement of Acute Myeloid Leukemia Mimicking Transfusion-related Acute Lung Injury

Kobayashi T, Nannya Y, Ichikawa M, Oritani K, Kanakura Y, Tomita A, Kiyoi H, Kobune M, Kato J, Kawabata H, Shindo M, Torimoto Y, Yonemura Y, Hanaoka N, Nakakuma H, Hasegawa D, Manabe A, Fujishima N, Fujii N, Tanimoto M, Morita Y, Matsuda A, Fujieda A, Katayama N, Ohashi H, Nagai H, Terada Y, Hino M, Sato K, Obara N, Chiba S, Usuki K, Ohta M, Imataki O, Uemura M, Takaku T, Komatsu N, Kitanaka A, Shimoda K, Watanabe K, Tohyama K, Takaori-Kondo A, Harigae H, Arai S, Miyazaki Y, Ozawa K, Kurokawa M; for National Research Group on Idiopathic Bone Marrow Failure Syndromes.
@
A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study)..

Maruyama D, Nagai H, Maeda Y, Nakane T, Shimoyama T, Nakazato T, Sakai R, Ishikawa T, Izutsu K, Ueda R, Tobinai K
@
Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma..

Koh S, Koh H, Kubo Y, Kuroda M, Nishimoto M, Yoshimura T, Nakashima Y, Nakane T, Nakamae H, Ohsawa M, Hino M
@
An Elderly Woman with Anti-neutrophil Antibody-positive Agranulocytosis Who Responded to High-dose Intravenous Methylprednisolone.

Koh H, Nanno S, Hino M, Nakamae H
@
Diagnostic value of serum ferritin and cytokine profiles of hemophagocytic syndrome following allogeneic hematopoietic cell transplantation: methodological issues.

Kasashima H, Yashiro M, Nakamae H, Masuda G, Kinoshita H, Morisaki T, Fukuoka T, Hasegawa T, Nakane T, Hino M, Hirakawa K, Ohira M.
@
Clinicopathologic significance of the CXCL1-CXCR2 axis in the tumor microenvironment of gastric carcinoma.

Kondo T, Nagamura-Inoue T, Tojo A, Nagamura F, Uchida N, Nakamae H, Fukuda T, Mori T, Yano S, Kurokawa M, Ueno H, Kanamori H, Hashimoto H, Onizuka M, Takanashi M, Ichinohe T, Atsuta Y, Ohashi K..
@
Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.

Tojo A, Kyo T, Yamamoto K, Nakamae H, Takahashi N, Kobayashi Y, Tauchi T, Okamoto S, Miyamura K, Hatake K, Iwasaki H, Matsumura I, Usui N, Naoe T, Tugnait M, Narasimhan NI, Lustgarten S, Farin H, Haluska F, Ohyashiki K..
@
Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study

Nakane T, Nakamae M, Koh H, Nishimoto M, Nakashima Y, Hirose A, Hino M, Nakamae H..
@
Autonomic Nervous System Pretransplant Malfunction is a Powerful Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation.

ÜŒ´ŸŒÈCŒá‹½_ŒúC‰œŽR”üŽ÷C—Ž‡—ºˆêCàV@³ŽjC“c–ìú±—²“ñC‹Êˆä‰ÀŽqC–L“ˆ’“¿C’†”öN•vC“ú–ì‰ë”VC‹{ú±‘׎iC_“c‘PLC‹àX•½˜a
@“ú–{œ‘ƒoƒ“ƒNƒhƒi[‚Ì‚Q‰ñœ‘’ñ‹Ÿ‚ÉŠÖ‚·‚錟“¢
“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïŽGŽ6(2): 108-114
’†‘O”ü‰À
@“¯Ží‘¢ŒŒŠ²×–EˆÚA‚ÌŠî‘b‚ƗՏ°ŒŸ¸‚ÌŠÖ‚í‚è
—Տ°•a—@65(3) 331-338, 2017

’†ªF•FAŽR‰º^—Žq
@“¯Ží‘¢ŒŒŠÇà–_ˆÚA‘OŒã‚É‚¨‚¯‚éŒÄ‹z‹@”\ŒŸ¸‚̈Ӌ`

—Տ°•a—@65(3) 351-354, 2017

¼–{ŒõFA‹gì~ˆê
@SƒGƒR[ŒŸ¸

—Տ°•a—@65(3) 355-360, 2017

Yamasaki S, Suzuki R, Hatano K, Fukushima K, Iida H, Morishima S, Suehiro Y, Fukuda T, Uchida N, Uchiyama H, Ikeda H, Yokota A, Tsukasaki K, Yamaguchi H, Kuroda J, Nakamae H, Adachi Y, Matsuoka KI, Nakamura Y, Atsuta Y, Suzumiya J.
@
Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma.

Nakamae H, Fujisawa S, Ogura M, Uchida T, Onishi Y, Taniwaki M, Utsunomiya A, Matsue K, Takamatsu Y, Usuki K, Tanimoto M, Ishida Y, Ohashi K, Li L, Miyoshi M.
@
Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report.

Nishimoto M, Koh H, Tokuwame A, Makuuchi Y, Kuno M, Takakuwa T, Okamura H, Koh S, Yoshimura T, Nanno S, Nakamae M, Hirose A, Nakashima Y, Nakane T, Hino M, Nakamae H.
@
Drug interactions and safety profiles with concomitant use of caspofungin and calcineurin inhibitors in allogeneic hematopoietic cell transplantation.

Nishimoto M, Nakamae H, Matsumoto K, Morita K, Koga Y, Momose D, Hino M.
@
Dasatinib and Prednisolone Induction Therapy for a Case of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Dilated Cardiomyopathy Accompanied by Life-Threatening Ventricular Tachycardia.

Koh H, Nanno S, Katayama T, Hirose A, Nakamae M, Hino M, Nakamae H..
@
Diagnostic usefulness of plasma presepsin (soluble CD14-subtype) for diagnosing hemophagocytic syndrome in hematological malignancies.

Murata M, Ikegame K, Morishita Y, Ogawa H, Kaida K, Nakamae H, Ikeda T, Nishida T, Inoue M, Eto T, Kubo K, Sakura T, Mori T, Uchida N, Ashida T, Matsuhashi Y, Miyazaki Y, Ichinohe T, Atsuta Y, Teshima T.
@
Low-dose thymoglobulin as second-line treatment for steroid-resistant acute GvHD: an analysis of the JSHCT.

Nakane T, Nakamae H, Yamaguchi T, Kurosawa S, Okamura A, Hidaka M, Fuji S, Kohno A, Saito T, Aoyama Y, Hatanaka K, Katayama Y, Yakushijin K, Matsui T, Yamamori M, Takami A, Hino M, Fukuda T.
@
Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem-cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials.

Nanno S, Koh H, Nakashima Y, Katayama T, Okamura H, Koh S, Yoshimura T, Nishimoto M, Hayashi Y, Nakamae M, Hirose A, Nakane T, Hino M, Nakamae H.
@
Diagnostic value of serum ferritin and the risk factors and cytokine profiles of hemophagocytic syndrome following allogeneic hematopoietic cell transplantation.

Kobayashi R, Mitsui T, Fujita N, Osumi T, Aoki T, Aoki K, Suzuki R, Fukuda T, Miyamoto T, Kato K, Nakamae H, Goto H, Eto T, Inoue M, Mori T, Terui K, Onizuka M, Koh K, Koga Y, Ichinohe T, Sawada A, Atsuta Y, Suzumiya J.
@
Outcome differences between children and adolescents and young adults with non-Hodgkin lymphoma following stem cell transplantation.

’†‘O”Ž‹v
@ˆÚAŒã‘å—Êcyclophosphamide‚ð—p‚¢‚½HLA”¼‡’vˆÚA
¬àVŒh–çA’†”öáÁ“ñA¼‘º@“ž•Ò@ŒŒ‰tŽ¾Š³ÅV‚ÌŽ¡—Ã2017|2019@“ì]“°,p.40-44,2017
“ú–ì‰ë”V
@ŒŒ‰tŽîᇂɂæ‚é•nŒŒ‚Ì—\–h¥ŠÇ—
“ú–{—Տ°A•nŒŒŠw,p559-563,2017

 

(Šw‰ï)

‘æ64‰ñ“ú–{—Տ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï
‹ž“s@11ŒŽ16“ú-19“ú
035@––½ŒŒ‰t•W–{ã‚ÉAlder-Reilly anomaly‚ð”F‚ß‚½ƒ€ƒR‘½“œÇVIIŒ^‚Ì‚PÇ—á
¡ˆäd—ǁA’†‘O”ü‰ÀA‹v•Û“c@_A“¡‰ªˆê–çA“ú–ì‰ë”V

 

‘æ108‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
‘åã@11ŒŽ18“ú
’°ŠÔ–ŒŽîᎂŔ­Ç‚µ‚½ŒÀ‹ÇŠúßŠO«NK/T×–EƒŠƒ“ƒpŽîA•@Œ^iENKLj‚Ì‚P—á
ì“Y–ƒˆßiˆãŠw•”6”N¶jA“cŠ_“à—D”üA“ì–ì@’qA¼–{ŒõFA•‰ªNMA’†“ˆN”ŽA’†ªF•FAN@G’jA’†‘O”Ž‹vA“ú–ì‰ë”V

 

‘æ60‰ñ“ú–{—Տ°ŒŸ¸ˆãŠw‰ï‹ß‹EŽx•”‘‰ï
‹ž“s@10ŒŽ28“ú
ƒAƒNƒZƒX@ƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXR‘ÌŽŽ–ò‚É‚©‚ñ‚·‚éŠî‘b“IŒŸ“¢
Šâ–{^Œ‹ŽqA¡ˆäd—ǁAìŒ´GŒbA‘å‰Yˆ»ŽqA“¡‰ªˆê–çA“ú–ì‰ë”V

 

‘æ79‰ñ“ú–{ŒŒ‰tŠw‰ï@

“Œ‹ž@10ŒŽ20“ú-22“ú
OS1-4C-1
^«‘½ŒŒÇ‚¨‚æ‚Ñ–{‘Ԑ«ŒŒ¬”ÂŒŒÇ‚É‚¨‚¯‚éƒTƒCƒgƒJƒCƒ“ƒvƒƒtƒ@ƒCƒ‹‚Ì•ªÍ

‚ŒK‹PlA’†‘O”ü‰ÀA“ì–ì@’qA¼–{ŒõFA’†“ˆN”ŽAN@G’jA’†ªF•FA•‰ªNMA“ú–ì‰ë”VA’†‘O”ü‰À
OS2-9B-4
”­ì«–éŠÔŒŒF‘f”AÇŠ³ŽÒ‚É‚¨‚¯‚銈«Ž_‘f‚ÆŒŒðÇ.

N@Žj˜NAN@G’jA“y‰®³•FA•ÐŽR‹MŽqA¼–{ŒõFA’†ªF•FAœA£’©¶A’†‘O”ü‰ÀAÂŽR‘׍FA•½ˆä@ŠwA”ž’JˆÀ’ÃŽqA’†‘O”Ž‹vA“ú–ì‰ë”V
PS2-44-2
ƒNƒ‰ƒhƒŠƒrƒ“‚ª‘tŒø‚µ‚½Hairy cell leukemia-Japanese variant‚̈ê—á

’†ªF•FA‰ª‘º_ŽjAâˆä“c‹IŽqA“¡ˆäˆê‹MA’†“ˆN”ŽAN@G’jA’†‘O”Ž‹vA‘åàV­•FA“ú–ì‰ë”V
PS2-25-1
“–Ž{Ý‚É‚¨‚¯‚鐬lT×–E”’ŒŒ•a/ƒŠƒ“ƒpŽî17—á‚ɑ΂·‚郂ƒKƒ€ƒŠƒYƒ}ƒu‚ÌŽ¡—ÃŒø‰Ê‚ÌŒŸ“¢

‚@‹N—ǁi‘åã“S“¹•a‰@jAŠâ‰i³ŽqA•S£@‘åAŠÔ•”Œ«Š°A›–ìˆÀŠìA“ú–ì‰ë”V
PS2-2-3
S?‰t’™—¯4”NŒã‚ɐf’f‚³‚ꂽS‘ŸŒ´”­ˆ««ƒŠƒ“ƒpŽî

–x“à”ü—߁i‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA’†”ö—²•¶A’ç@”üØŽqA’†ŽÉ—m•ãA•š‰®”¿—I—¢A‹g‘º‘ì˜NA—с@—ÇŽ÷A‹à“‡@LA”‹Œ´Œ‰’ʁA•Ÿ“‡—TŽqAˆäã@Œ’AŽRªF‹v
OS3-10A-1
“ú–{lDLBCLŠ³ŽÒ‚É‚¨‚¯‚éƒIƒrƒkƒcƒYƒ}ƒu‚Ì—LŒø«‚¨‚æ‚шÀ‘S«FGOYAŽŽŒ±•”•ªW’c‰ðÍ

—Š@W–çA’†‘O”Ž‹vA“à“crŽ÷A–L“ˆâM“¿A’†¢ŒÃ’mºAˆÉ“¤’ÍG“ñA”©@´•FA–k–ìrsAÔŽi_ˆêA’ߌ©@ŽõA‹à‘q@÷A’†“‡G–¾Aã“c‹±“TA’·“¡GŽiA‘å—ä@ŒªA”ò“àŒ«³A—é‹{~ŽiAÎ“c—zŽ¡A’£@‚–¾A“c‘ºGlAÎì—²”VAã“c‰p“TA‹v—́@—mA’C–¤—zˆê
OS3-10A-5
“ú–{lÄ”­E“«––½«T×–EƒŠƒ“ƒpŽîŠ³ŽÒ‚ð‘ΏۂƂµ‚½ƒvƒ‰ƒ‰ƒgƒŒƒLƒT[ƒg‚Ì‘æ1/2‘Š—Տ°ŽŽŒ±

“¿‰i—²”VA”ò“àŒ«³A‰iˆäG˜aA‘O“c‰ÃMA’†ªF•FA‰ºŽR@’BA’‡—¢’©ŽüAŽðˆäƒŠƒJAÎì—²”VAˆÉ“¤’ÍG“ñAã“c—´ŽO
OS2-4B-5
ŠÖ¼ƒ~ƒGƒ[ƒ}ƒtƒH[ƒ‰ƒ€‚É“o˜^‚³‚ꂽ‘½”­«œ‘ŽîŠ³ŽÒ‚ɑ΂·‚éKRD—Ö@‚ÌŽ¡—ÃŒø‰Ê‚ÌŒã•ûŽ‹“I‰ðÍ

‰¶“c‰ÀKAæ|“c~–çA‹àŽqmbAŽÄŽR_•FAŽu‘º—EŽiA‘¾“cŒ’‰îA“c’†G˜aA•£“c^ˆêA¼“cŒõOA’†’J@ˆ»A“àŽRlmA‹›“ˆL•FA¬™@’qA¡“c˜a“TA“ú–ì‰ë”VA–쑺¹ìA“‡èçqA•“cƒ–çA‹à‘q@÷A‚Üi‹ß“¡jjWŽjA¼‘º@“ž
OS3-‚P‚TA-1
KMF‚É“o˜^‚³‚ꂽ‘½”­«œ‘ŽîŠ³ŽÒ‚É‚¨‚¯‚銲×–EÌŽæ•s—Ç‚ÌŒã•ûŽ‹“I‰ðÍ

•£“c^ˆêA‹àŽqmbAŽÄŽR_•FAŽu‘º—EŽiA‘¾“cŒ’‰îA’†’J@ˆ»A¬™@’qAAæ|“c~–çA”ª–؏G’jA“c’†G˜aA“àŽRlmAã’Ò—R—¢A‰G–ìF”ŽAV“°^‹IA‘«—§—zŽqA‰Í“c‰p—¢A¼“cŒõOA‹›“ˆL•FAÎì@~A¡“c˜a“TA‹à‘q@÷A•“cƒ–çA“ú–ì‰ë”VA–쑺¹ìA‚Üi‹ß“¡jjWŽjA“‡èçqA¼‘º@“ž

OS3-‚P‚TA-5
ÇŒó«‘½”­«œ‘Žî‚ɑ΂·‚鎩‰Æ––½ŒŒŠ²×–EˆÚAŒã‚Ì’nŒÅ‚ߗÖ@‚¨‚æ‚шێ—Ö@‚Ì—L—p«

’†’J@ˆ»A‹àŽqmbAŽÄŽR_•FAŽu‘º—EŽiAæ|“c~–çAV“°^‹IA‘¾“cŒ’‰îA¬™@’qA•£“c^ˆêA”ª–؏G’jA“c’†G˜aAã’Ò—R—¢A‰G–ìF”ŽA‹›“ˆL•FA‰Í“c‰p—¢A‘«—§—zŽqA“àŽRlmA¼ˆä—˜ŒõA¼“cŒõOAÎì@~Aà_“cí‹`A‚‹´—LjêA¡“c˜a“TA“‡èçqA“ú–ì‰ë”VA•“cƒ–çA‹à‘q@÷A‚Üi‹ß“¡jjWŽjA–쑺¹ìA¼‘º@“ž

OS3-‚P‚TB-3
ƒvƒ‰ƒg[‚ÍŠùŽ¡—ѽ”­«œ‘Žî‚ɑ΂·‚郌ƒiƒŠƒhƒ~ƒhŽ¡—Â̗\ŒãˆöŽq‚Å‚ ‚é

‘¾“cŒ’‰îAr–؁@‘ñA’†’J@ˆ»A‹àŽqmbA•£“c^ˆêAŽu‘º—EŽiA”ª–؏G’jAŽÄŽR_•FAæ|“c~–çA“àŽRlmA¬™@’qA“c’†G˜aA‰Í“c‰p—¢A‹›“ˆL•FAÎì@~A¬Œ´®ŒbA‰G–ìF”ŽAV“°^‹IA‚‹´—²KA´…‹`•¶A’†’J‰pmA¡“c˜a“TA‹à‘q@÷A•“cƒ–çA“ú–ì‰ë”VA–쑺¹ìA‚Üi‹ß“¡jjWŽjA“‡èçqA¼‘º@“ž
OS3-‚P‚TB-5
’´‚—î(80ÎˆÈãjÇŒó«‘½”­«œ‘Žî‚ɑ΂·‚鎡—ЬÑFKMF‚É‚¨‚¯‚éŒã•ûŽ‹“I‰ðÍ

Žu‘º—EŽiA‹àŽqmbA’†’J@ˆ»A¬™@’qA•£“c^ˆêA“c’†G˜aA‘¾“cŒ’‰îAŽÄŽR_•FA‹›“ˆL•FAæ|“c~–çA”ª–؏G’jA¼ˆä—˜ŒõAã’Ò—R—¢A¼“cŒõOA‘«—§—zŽqA‰G–ìF”ŽA‰Í“c‰p—¢A“àŽRlmAìã@ŠwA¬Œ´®ŒbA¡“c˜a“TA“‡èçqA“ú–ì‰ë”VA‹à‘q@÷A‚Üi‹ß“¡jjWŽjA–쑺¹ìA•“cƒ–çA¼‘º@“ž

 

‘æ217‰ñ“ú–{“à‰»Šw‰ï‹ß‹E’n•û‰ï
‘åã@9ŒŽ16“ú
’°ƒŠƒ“ƒpŠÇŠg’£Ç‚ÌŒo‰ß’†‚É”­Ç‚µ‚½‚Ñ‚Ü‚ñ«‘å×–EŒ^B×–E«ƒŠƒ“ƒpŽî
’†ˆä‹vŽÀ‘ãA•‰ªNMA’†ªF•FA“ì–ì@’qA¼–{ŒõFA“ú–ì‰ë”VAŽRã”Žˆê

 

‘æ107‰ñ‹ß‹EŒŒ‰tŠw’n•û‰ï
‹ž“s@6ŒŽ17“ú
ˆÚA‘OƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXIgG‰A«‚ð’悵‚½ƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXö•šŠ´õƒŒƒVƒsƒGƒ“ƒg
ˆäŒËŒ’‘¾˜Yi¶’·‰ï•{’†•a‰@jAN@Žj˜NAŽsŒ´O‘PAÂŽR‘׍FA”ž’JˆÀ’ÃŽqA’†‘O”Ž‹vA“ú–ì‰ë”VA’J@Œc•F

 

‘æ39‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ï
¼]@3ŒŽ2“úE4“ú
P6-3
ƒ`ƒƒVƒ“ƒLƒi[ƒ[‘jŠQ–òŽž‘ã‚̃tƒBƒ‰ƒfƒ‹ƒtƒBƒAõF‘Ì—z«‹}«ƒŠƒ“ƒp«”’ŒŒ•a‚ɑ΂·‚铯Ží‘¢ŒŒŠ²×–EˆÚA‚Ì—LŒø«
ˆäŒËŒ’‘¾˜Yi¶’·‰ï•{’†•a‰@jAN@Žj˜NAŽsŒ´O‘PAÂŽR‘׍FA”ž’JˆÀ’ÃŽq
P14-2
¬l“¯Ží‘¢ŒŒŠ²×–EˆÚAŠ³ŽÒ‚̃AƒfƒmƒEƒCƒ‹ƒXoŒŒ«äNã÷‰Š‚ɑ΂·‚éƒVƒhƒtƒHƒrƒ‹Ž¡—Â̌ã•ûŽ‹“IŒ¤‹†
‹g‘º‘ì˜NA¼–{ŒõFA’†ªF•FAN@G’jA’†“ˆN”ŽA•‰ªNMA’†‘O”ü‰ÀAœA£’©¶A“ú–ì‰ë”VA’†‘O”Ž‹v
P16-4
‘ŠúŠm’èf’f‚Énested PCR–@‚ª—L—p‚Å‚ ‚Á‚½AHLA”¼‡’v“¯Ží‘¢ŒŒŠ²×–EˆÚAŒã‚ɐ¶‚¶‚½ƒgƒLƒ\ƒvƒ‰ƒYƒ}”]‰Š‚̈ê—á
–‹“à—z‰îA¼–{ŒõFA—с@—ÇŽ÷A‹v–ì‰ë’qA•FâŒšŽ™A²“¡“N¶AŽR“cNˆêA’†“ˆN”ŽAN@G’jA’†ªF•FA–ì˜C£ˆê”üA‹àŽqKOAŠ|‰®@OA“ú–ì‰ë”VA’†‘O”Ž‹v
P12-6
‘ŠúŠm’èf’f‚Énested PCR–@‚ª—L—p‚Å‚ ‚Á‚½AHLA”¼‡’v“¯Ží‘¢ŒŒŠ²×–EˆÚAŒã‚ɐ¶‚¶‚½ƒgƒLƒ\ƒvƒ‰ƒYƒ}”]‰Š‚̈ê—á
–x“à”ü—߁i‘åãŽs—§‘‡ˆã—ÃZƒ“ƒ^[jA—с@—ÇŽ÷A’ç@”üØŽqA•š‰®”¿—I—¢A”‹Œ´Œ‰’ʁA‹à“‡@LA’†”ö—²•¶Aˆäã@Œ’AŽRªF‹v
P4-6
‚킪‘‚É‚¨‚¯‚錌‰ŽÒŠÔ––½ŒŒŠ²×–E“€Œ‹‚ÌŽÀ‘Ô‚Ì”cˆ¬‚Ì‚½‚߂̃Aƒ“ƒP[ƒg’²¸
¬—с@•A‘å‹´ˆê‹PAŒ´Œû‹žŽqA‰œŽR”üŽ÷A“ú–ì‰ë”VA“c’†~ŽiAã“c‹±“TA¼“c“O–çA”M“c—RŽqA‚—œ”ü”TŽqA”Ñ“c”ü“ÞŽqAŽºˆäˆê’jA–î•”W³A‹{‘ºkˆê

 

BMT tandem meeting 2017
Orlando@2ŒŽ22“úE26“ú
P
Cidofovir treatment for adenovirus-associated hemorrhagic cystitis in adult recipients of allogeneic hematopoietic stem cell transplantation: a retrospective comparative study
Yoshimura T, Nishimono M, Nakane T, Koh H, Nakashima Y, Takeoka Y, Nakamae M, Hirose A, Hino M, Nakamae H

 

5rd International Symposium of Training Plan for Oncology Professionals

‘åãA3ŒŽ12“ú
Immunoprofile changes during dasatinib treatment in patients with chronic myeloid leukemia: a prospective observational study.
Kuno M

 

–ß‚é